LEADER 04657nam  22010813u 450 
001 9910780301103321
005 20230607213857.0
010   $a0-309-50374-4
035   $a(CKB)111069351130742
035   $a(EBL)3375300
035   $a(SSID)ssj0000106797
035   $a(PQKBManifestationID)11138488
035   $a(PQKBTitleCode)TC0000106797
035   $a(PQKBWorkID)10132373
035   $a(PQKB)10978189
035   $a(MiAaPQ)EBC3375300
035   $a(EXLCZ)99111069351130742
100   $a20170301d2002||||  u||            |
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 10$aAssessment of the CDC Anthrax vaccine safety and efficacy research program$b[electronic resource]
210   $aWashington $cNational Academies Press$d2002
215   $a1 online resource (179 p.)
300   $aDescription based upon print version of record.
311   $a0-309-08626-4 
327   $a""Front Matter""; ""Preface""; ""Reviewers""; ""Contents""; ""Figures, Tables, and Boxes""; ""Abbreviations and Acronyms""; ""Executive Summary""; ""1 Introduction""; ""2 Background""; ""3 The CDC Anthrax Vaccine Research Plan""; ""4 Proposed Studies on the Efficacy of the Anthrax Vaccine""; ""5 Proposed Studies on the Safety of the Anthrax Vaccine""; ""6 Proposed Studies on the Acceptability of the Anthrax Vaccine""; ""7 Summary Assessment of the CDC Anthrax Vaccine Research Plan""; ""Appendix A Biographical Sketches""; ""Appendix B Information-Gathering Meeting Agendas""
327   $a""Appendix C Anthrax Vaccine Safety & Efficacy Research Plan""""Appendix D Food and Drug Administration Final Rule: New Drug and Biological Drug Products;  Evidence Needed to Demonstrate Effectiveness of New Drugs When Human Efficacy Studies Are Not Ethical or Feasible""; ""Appendix E Department of Defense Memorandum: Reintroduction of the Anthrax Vaccine Immunization Program""; ""Appendix F Institute of Medicine: CDC Anthrax Vaccine Safety & Efficacy Research Program. Interim Report Findings and Recommendations1""
327   $a""Appendix G Institute of Medicine: The Anthrax Vaccine: Is It Safe? Does It Work? Findings and Recommendations1""
606   $aAnthrax -- Vaccination
606   $aPublic health
606   $aAnthrax$xVaccination$xResearch$zUnited States
606   $aBacterial Vaccines
606   $aEvaluation Studies as Topic
606   $aHealth Care Evaluation Mechanisms
606   $aQuality of Health Care
606   $aBacillaceae Infections
606   $aInvestigative Techniques
606   $aVaccines
606   $aHealth Services Administration
606   $aGram-Positive Bacterial Infections
606   $aBacterial Infections
606   $aHealth Care Quality, Access, and Evaluation
606   $aHealth Care
606   $aBiological Products
606   $aComplex Mixtures
606   $aBacterial Infections and Mycoses
606   $aDiseases
606   $aProgram Evaluation
606   $aDrug Evaluation
606   $aAnthrax
606   $aAnthrax Vaccines
606   $aPublic Health$2HILCC
606   $aHealth & Biological Sciences$2HILCC
606   $aCommunicable Diseases$2HILCC
615  4$aAnthrax -- Vaccination.
615  4$aPublic health.
615  0$aAnthrax$xVaccination$xResearch
615  2$aBacterial Vaccines
615  2$aEvaluation Studies as Topic
615  2$aHealth Care Evaluation Mechanisms
615  2$aQuality of Health Care
615  2$aBacillaceae Infections
615  2$aInvestigative Techniques
615  2$aVaccines
615  2$aHealth Services Administration
615  2$aGram-Positive Bacterial Infections
615  2$aBacterial Infections
615  2$aHealth Care Quality, Access, and Evaluation
615  2$aHealth Care
615  2$aBiological Products
615  2$aComplex Mixtures
615  2$aBacterial Infections and Mycoses
615  2$aDiseases
615  2$aProgram Evaluation
615  2$aDrug Evaluation
615  2$aAnthrax
615  2$aAnthrax Vaccines
615  7$aPublic Health
615  7$aHealth & Biological Sciences
615  7$aCommunicable Diseases
676   $a615
700   $aStaff$b Institute of Medicine$01462487
712 02$aInstitute of Medicine (U.S.) Committee to Review the CDC Anthrax Vaccine Safety and Efficacy Research Program.
801  0$bAU-PeEL
801  1$bAU-PeEL
801  2$bAU-PeEL
906   $aBOOK
912   $a9910780301103321
996   $aAssessment of the CDC Anthrax vaccine safety and efficacy research program$93671491
997   $aUNINA